{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:08:50Z","timestamp":1782817730342,"version":"3.54.5"},"reference-count":30,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MRC Grant","award":["MC_UU_12023\/27."],"award-info":[{"award-number":["MC_UU_12023\/27."]}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["RP-PG-0217-20009"],"award-info":[{"award-number":["RP-PG-0217-20009"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UCLH\/UCL Biomedical Research Centre Patient & Public Involvement bursary fund","award":["No grant number"],"award-info":[{"award-number":["No grant number"]}]},{"name":"NIHR Clinical Research Network","award":["No grant number"],"award-info":[{"award-number":["No grant number"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The successful scale-up of a latent tuberculosis (TB) infection testing and treatment programme is essential to achieve TB elimination. However, poor adherence compromises its therapeutic effectiveness. Novel rifapentine-based regimens and treatment support based on behavioural science theory may improve treatment adherence and completion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>A pragmatic multicentre, open-label, randomised controlled trial assessing the effect of novel short-course rifapentine-based regimens for TB prevention and additional theory-based treatment support on treatment adherence against standard-of-care. Participants aged between 16 and 65 who are eligible to start TB preventive therapy will be recruited in England. 920 participants will be randomised to one of six arms with allocation ratio of 5:5:6:6:6:6: daily isoniazid +rifampicin for 3 months (3HR), routine treatment support (control); 3HR, additional treatment support; weekly isoniazid +rifapentine for 3 months (3HP), routine treatment support; weekly 3HP, additional treatment support ; daily isoniazid +rifapentine for 1 month (1HP), routine treatment support; daily 1HP, additional treatment support. Additional treatment support comprises reminders using an electronic pillbox, a short animation, and leaflets based on the perceptions and practicalities approach. The primary outcome is adequate treatment adherence, defined as taking \u226590% of allocated doses within the pre-specified treatment period, measured by electronic pillboxes. Secondary outcomes include safety and TB incidence within 12 months. We will conduct process evaluation of the trial interventions and assess intervention acceptability and fidelity and mechanisms for effect and estimate the cost-effectiveness of novel regimens. The protocol was developed with patient and public involvement, which will continue throughout the trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>Ethics approval has been obtained from The National Health Service Health Research Authority (20\/LO\/1097). All participants will be required to provide written informed consent. We will share the results in peer-reviewed journals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>EudraCT 2020-004444-29.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2021-057717","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T15:38:24Z","timestamp":1662478704000},"page":"e057717","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for an open-label, multicentre, randomised controlled trial"],"prefix":"10.1136","volume":"12","author":[{"given":"Molebogeng X","family":"Rangaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9845-4267","authenticated-orcid":false,"given":"Yohhei","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinh","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Bern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Louise","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Ghanouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Layton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Hack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Owen-Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Surey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen L","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7935-8694","authenticated-orcid":false,"given":"Chris","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinke","family":"Kunst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7501-4448","authenticated-orcid":false,"given":"Marc","family":"Lipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Mandelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Zenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-1430","authenticated-orcid":false,"given":"Ibrahim","family":"Abubakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"2022090608252127000_12.9.e057717.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00214014"},{"key":"2022090608252127000_12.9.e057717.2","unstructured":"World Health Organization . Call to action 2.0: a global drive to scale up TB.. Available: https:\/\/cdn.who.int\/media\/docs\/default-source\/hq-tuberculosis\/call-to-action-2.0-a-global-drive-to-scale-up-tb-prevention.pdf?sfvrsn=6f938b38_7&download=trueT_scaleup.pdf?u=f093a7c38a3780cd9504f8d9d&id=135bdee6af&e=09bced52fa [Accessed 8 July 2021]."},{"key":"2022090608252127000_12.9.e057717.3","unstructured":"England PH . Collaborative tuberculosis strategy for England: 2015 to 2020 2015."},{"key":"2022090608252127000_12.9.e057717.4","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0373"},{"key":"2022090608252127000_12.9.e057717.5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.5588\/ijtld.13.0486","article-title":"Predictors of contact tracing completion and outcomes in tuberculosis: a 21-year retrospective cohort study","volume":"18","author":"Saunders","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2022090608252127000_12.9.e057717.6","unstructured":"Public Health England: . LTBI testing and treatment programme for migrants: report.; 2020."},{"key":"2022090608252127000_12.9.e057717.7","unstructured":"Public Health England: . Tuberculosis in England. 2020 report.; 2020."},{"key":"2022090608252127000_12.9.e057717.8","unstructured":"Public Health England: . LTBI testing and treatment programme for migrants 2020: data tables.; 2020."},{"key":"2022090608252127000_12.9.e057717.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2007.05.004"},{"key":"2022090608252127000_12.9.e057717.10","unstructured":"NICE . Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence: full guideline.. Clinical Guideline CG76 2009."},{"key":"2022090608252127000_12.9.e057717.11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1027\/1016-9040\/a000353","article-title":"Supporting adherence to medicines for long-term conditions: a perceptions and practicalities approach based on an extended common-sense model","volume":"24","author":"Horne","year":"2019","journal-title":"European Psychologist"},{"key":"2022090608252127000_12.9.e057717.12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001876"},{"key":"2022090608252127000_12.9.e057717.13","first-page":"387","volume-title":"MMWR morbidity and mortality Weekly report","volume":"66","author":"Holzschuh","year":"2017"},{"key":"2022090608252127000_12.9.e057717.14","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.9825","article-title":"Using video technology to increase treatment completion for patients with latent tuberculosis infection on 3-month isoniazid and rifapentine: an implementation study","volume":"20","author":"Lam","year":"2018","journal-title":"J Med Internet Res"},{"key":"2022090608252127000_12.9.e057717.15","unstructured":"World Health Organization . Overcoming key barriers to scale up tuberculosis preventive treatment (TPT) a call to action.. Available: https:\/\/www.who.int\/tb\/CalltoactionTPT_scaleup.pdf?u=f093a7c38a3780cd9504f8d9d&id=135bdee6af&e=09bced52fa [Accessed 18 May 2021]."},{"key":"2022090608252127000_12.9.e057717.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"key":"2022090608252127000_12.9.e057717.17","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0609"},{"key":"2022090608252127000_12.9.e057717.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806808"},{"key":"2022090608252127000_12.9.e057717.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080633"},{"key":"2022090608252127000_12.9.e057717.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-021-05766-9","article-title":"An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the halt LTBI pilot study","volume":"21","author":"Surey","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2022090608252127000_12.9.e057717.21","unstructured":"Public Health England: . Latent TB testing and treatment for migrants. A practical guide for commissioners and practitioners.; 2015."},{"key":"2022090608252127000_12.9.e057717.22","unstructured":"evriMED1000 dispenser [. Available: https:\/\/www.wisepill.com\/wisepill-rm1000 [Accessed 9 July 2021]."},{"key":"2022090608252127000_12.9.e057717.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005136"},{"key":"2022090608252127000_12.9.e057717.24","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med Overseas Ed"},{"key":"2022090608252127000_12.9.e057717.25","unstructured":"Office for National Statistics . Families and households in the UK:, 2020. Available: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/families\/bulletins\/familiesandhouseholds\/2020 [Accessed 15 Sep 2021]."},{"key":"2022090608252127000_12.9.e057717.26","unstructured":"Public Health England: . Tuberculosis in England. 2019 report.; 2019."},{"key":"2022090608252127000_12.9.e057717.27","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1177\/0962280216664759","article-title":"Recommendations on multiple testing adjustment in multi-arm trials with a shared control group","volume":"27","author":"Howard","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"2022090608252127000_12.9.e057717.28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/1740774520904346","article-title":"Adding new experimental arms to randomised clinical trials: impact on error rates","volume":"17","author":"Choodari-Oskooei","year":"2020","journal-title":"Clin Trials"},{"key":"2022090608252127000_12.9.e057717.29","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-364"},{"key":"2022090608252127000_12.9.e057717.30","unstructured":"US , Health Dof , Services H . National Institutes of health, National Institute of allergy and infectious diseases, division of AIDS. division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1, 2017. Available: https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf [Accessed July11 September 2020]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-057717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T15:38:47Z","timestamp":1662478727000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-057717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,6]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/bmjopen-2021-057717"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-057717","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}